Skip to content

Subendocardial Viability Ratio in Hypertension

Subendocardial Viability Ratio in Hypertension

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06309511
Acronym
SEVR-HT
Enrollment
3000
Registered
2024-03-13
Start date
2022-10-01
Completion date
2026-12-31
Last updated
2025-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Keywords

Myocardial ischemia, Buckberg index

Brief summary

The aim of the research is to evaluate the Subendocardial Viability Ratio (SEVR) in hypertensive patients, using non-invasive arterial tonometry, and to establish the influencing factors and the possibility of predicting cardiovascular morbidity and mortality in arterial hypertension. The SEVR will be evaluated on all patients belonging to the Arterial Hypertension Centers undergoing non-invasive arterial tonometry. The SEVR is calculated on the morphology of the central pressure wave as the ratio between the DPTI (diastolic pressure-time index), i.e. the area between the carotid pressure curve and the ventricular pressure curve during the diastolic phase, and the SPTI ( systolic pressure-time index), i.e. the area under the carotid pressure curve during the systolic phase. The SEVR will be correlated with the anthropometric and pathology variables which will be collected in an appropriate database.

Interventions

DIAGNOSTIC_TESTArterial tonometry

Arterial transcutaneous tonometry

Sponsors

Istituto Auxologico Italiano
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Hypertension

Exclusion criteria

* Atrial fibrillation

Design outcomes

Primary

MeasureTime frameDescription
Buckberg indexAt recruitment, at 1 year, 2 years, 3 years and 4 years of follow-upAssessment of subendocardial viability ratio (SEVR)

Countries

Italy

Contacts

Primary ContactPaolo Salvi, MD
p.salvi@auxologico.it+390261911

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026